home *** CD-ROM | disk | FTP | other *** search
- $Unique_ID{BRK03842}
- $Pretitle{}
- $Title{Hyperlipoproteinemia, Type IV}
- $Subject{Hyperlipoproteinemia, Type IV Carbohydrate-Induced Hyperlipemia
- Hyperprebeta-Lipoproteinemia Hypercholesterolemia Hyperlipidemia IV
- Hypertriglyceridemia, Endogenous Broad Beta Disease (Hyperlipoproteinemia,
- Type III) }
- $Volume{}
- $Log{}
-
- Copyright (C) 1988, 1989 National Organization for Rare Disorders, Inc.
-
- 624:
- Hyperlipoproteinemia, Type IV
-
- ** IMPORTANT **
- It is possible that the main title of this article (Hyperlipoproteinemia,
- Type IV) is not the name you expected. Please check the SYNONYM list to find
- the alternate names and disorder subdivisions covered by this article.
-
- Synonyms
-
- Carbohydrate-Induced Hyperlipemia
- Hyperprebeta-Lipoproteinemia
- Hypercholesterolemia
- Hyperlipidemia IV
- Hypertriglyceridemia, Endogenous
-
- Information on the following disorder can be found in the Related
- Disorders section of this report:
-
- Broad Beta Disease (Hyperlipoproteinemia, Type III)
-
- General Discussion
-
- ** REMINDER **
- The information contained in the Rare Disease Database is provided for
- educational purposes only. It should not be used for diagnostic or treatment
- purposes. If you wish to obtain more information about this disorder, please
- contact your physician and/or the agencies listed in the "Resources" section
- of this report.
-
- Hyperlipoproteinemia, Type IV, is an inherited metabolic disorder. It is
- characterized by an increased blood level of the fats called triglycerides
- which are contained in very low-density lipids (VLDL). An abnormally high
- level of triglycerides or cholesterol can result from diet, from genetic
- causes, or it may occur secondary to other metabolic disorders or as a side
- effect of certain drugs.
-
- Symptoms
-
- Hyperlipoproteinemia, Type IV, is characterized by an abnormally high level
- of cholesterol or triglycerides in the blood. Glucose (sugar) tolerance is
- usually also impaired. Eruptive fatty nodules or plaques in the skin
- (xanthomas) may develop on the buttocks, arms or legs. Hyperlipoproteinemia
- usually accelerates fatty degeneration of blood vessels, and coronary heart
- disease frequently develops. The liver and spleen may be enlarged
- (hepatosplenomegaly).
-
- Causes
-
- Hyperlipoproteinemia, Type IV, is an inherited disorder transmitted through
- autosomal dominant genes. (Human traits, including the classic genetic
- diseases, are the product of the interaction of two genes for that condition,
- one received from the father and one from the mother. In dominant disorders,
- a single copy of the disease gene (received from either the mother or father)
- will be expressed "dominating the other normal gene and resulting in
- appearance of the disease. The risk of transmitting the disorder from
- affected parent to offspring is 50 percent for each pregnancy regardless of
- the sex of the resulting child.)
-
- Onset of Hyperlipoproteinemia, Type IV, can be influenced by
- environmental factors such as too much carbohydrate in the diet or by
- excessive alcohol consumption. Other conditions that can cause
- Hyperlipoproteinemia IV are uremia, malfunction of the pituitary gland
- (hypopituitarism), contraceptive steroid drugs and other lipid storage
- diseases.
-
- Affected Population
-
- Hyperlipoproteinemia, Type IV, is a common disorder affecting males and
- females in equal numbers.
-
- Related Disorders
-
- Symptoms of the following disorder can be similar to those of
- Hyperlipoproteinemia, Type IV. Comparisons may be useful for a differential
- diagnosis:
-
- Broad Beta Disease (Hyperlipoproteinemia, Type III) is a hereditary
- disorder of fat (lipid) transport characterized by areas of lipid deposits
- (xanthomas) under certain parts of the skin. Patients with this disorder
- have a predisposition to obesity and fatty degeneration of blood vessels
- (atherosclerosis) which leads to blockage of blood vessels. With control of
- dietary lipids, persons affected with Broad Beta Disease can lead a normal
- life. (For more information, choose "Broad Beta" as your search term in the
- Rare Disease Database.)
-
- Therapies: Standard
-
- Treatment for Hyperlipoproteinemia, Type IV, consists in following a diet
- reduced in saturated fats, cholesterol, and calories. Drugs may also be
- required to lower cholesterol levels when diet alone is not effective.
-
- Therapies: Investigational
-
- This disease entry is based upon medical information available through
- December 1988. Since NORD's resources are limited, it is not possible to
- keep every entry in the Rare Disease Database completely current and
- accurate. Please check with the agencies listed in the Resources section for
- the most current information about this disorder.
-
- Resources
-
- For more information on Hyperlipoproteinemia, Type IV, please contact:
-
- National Organization for Rare Disorders (NORD)
- P.O. Box 8923
- New Fairfield, CT 06812-1783
- (203) 746-6518
-
- NIH/National Heart, Blood & Lung Institute
- 9000 Rockville Pike
- Bethesda, MD 20892
- (301) 496-4236
-
- American Heart Association
- 7320 Greenville Ave.
- Dallas, TX 75231
- (214) 750-5300
-
- For genetic information and genetic counseling referrals, please contact:
-
- March of Dimes Birth Defects Foundation
- 1275 Mamaroneck Avenue
- White Plains, NY 10605
- (914) 428-7100
-
- Alliance of Genetic Support Groups
- 35 Wisconsin Circle, Suite 440
- Chevy Chase, MD 20815
- (800) 336-GENE
- (301) 652-5553
-
- References
-
- DIETARY THERAPY FOR DIFFERENT FORMS OF HYPERLIPOPROTEINEMIA: S.M. Grundy;
- Circulation (September 1987: issue 76(3)). Pp. 523-528.
-
- GEMFIBROZIL THERAPY IN PRIMARY HYPERTRIGLYCERIDEMIA ASSOCIATED WITH
- CORONARY HEART DISEASE. EFFECTS ON METABOLISM OF LOW-DENSITY LIPOPROTEINS:
- G.L. Vega, et al.; Journal Amer Med Assoc (April 26, 1985: issue 253(16)).
- Pp. 2398-2403.
-
- DIFFERENT PATTERNS OF POSTPRANDIAL LIPOPROTEIN METABOLISM IN NORMAL, TYPE
- IIA, TYPE III, AND TYPE IV HYPERLIPOPROTEINEMIC INDIVIDUALS. EFFECTS OF
- TREATMENT WITH CHOLESTYRAMINE AND GEMFIBROZIL: M.S. Weintraub, et al.;
- Journal Clin Invest (April 1987: issue 79(4)). Pp. 1110-1119.
-
-